Home
    Disclaimer
    Nicotine molecular structure

    Nicotine Stats & Data

    Nic
    Psychoactive Class Stimulant
    Half-Life ~2 hours (nicotine; metabolized mainly by CYP2A6); cotinine metabolite ~16–18 hours

    Pharmacology

    DrugBank
    Half-life 20.0 hours Protein binding 5%

    Mechanism of Action

    Nicotine is a stimulant drug that acts as an agonist at nicotinic acetylcholine receptors. These are ionotropic receptors composed up of five homomeric or heteromeric subunits. In the brain, nicotine binds to nicotinic acetylcholine receptors on dopaminergic neurons in the cortico-limbic pathways. This causes the channel to open and allow conductance of multiple cations including sodium, calcium, and potassium. This leads to depolarization, which activates voltage-gated calcium channels and allo

    Metabolism

    Primarily hepatic, cotinine is the primary metabolite.

    Effect Profile

    Curated + 41 Reports
    Stimulant 8.4

    Strong euphoria, focus, anxiety/jitters, and stimulation

    Stimulation / Energy×3
    98.5
    Euphoria / Mood Lift×2
    107.7
    Focus / Productivity×2
    106.8
    Anxiety / Jitters×1
    109.2
    Catalog Erowid

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    ~2 hours (nicotine; metabolized mainly by CYP2A6); cotinine metabolite ~16–18 hours
    Addiction Potential
    High. Rapid reinforcement via nicotinic acetylcholine receptors with strong cue-linked craving and withdrawal; dependence is common with daily use.

    Tolerance Decay

    Full tolerance 3d Half tolerance 14d Baseline ~30d

    Tolerance to stimulant and autonomic effects rises quickly with daily use and decays over weeks; values are approximate and inferred from dependence literature and user reports rather than controlled dosing studies.

    Cross-Tolerances

    Other nicotinic agonists (e.g., cytisinicline, varenicline partial agonism differs)
    30% ●○○

    Experience Report Analysis

    Erowid
    41 Reports
    1997–2025 Date Range
    29 With Age Data
    20 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 41 experience reports (41 Erowid)

    41 Reports
    20 Effects Detected
    9 Positive
    4 Adverse
    7 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 9

    Euphoria 51.2% 70%
    Stimulation 51.2% 70%
    Focus Enhancement 34.1% 70%
    Music Enhancement 31.7% 70%
    Empathy 29.3% 70%
    Color Enhancement 26.8% 70%
    Tactile Enhancement 12.2% 70%
    Introspection 9.8% 70%
    Body High 7.3% 70%

    Adverse Effects 4

    Anxiety 46.3% 70%
    Nausea 39.0% 70%
    Confusion 19.5% 70%
    Increased Heart Rate 7.3% 70%

    Form / Preparation

    Most common forms and preparations reported

    Redose Patterns

    Redosing behavior across 25 reports

    16.0% Redosed
    1.2 Avg Doses
    260m Median Interval

    Harm Reduction

    drugs.wiki

    Reasoning for changes (key harm-reduction facts and sources): Nicotine dosing is highly route-dependent. Inhalation gives a near-immediate spike with short primary duration, while buccal products act slower/longer and patches provide stable, lower peaks—these differences influence overdose risk and redosing behavior. Erowid’s dosage page summarizes smoked, oral/buccal, intranasal ranges and typical patch delivery rates; the NCI PDQ shows marketed patch strengths and usage durations. These sources support the corrected/expanded ROA-specific dosing and time-course fields. Nicotine poisoning risk is significant with concentrated e-liquids and dermal/ocular exposure; national reviews document severe outcomes and rare fatalities, emphasizing glove use, child-resistant storage, and avoiding decanting into drink-like containers. Pure nicotine is not the primary driver of combustion-related disease; switching from smoking to nicotine-only products removes smoke toxicants and CYP1A2 induction, which can unexpectedly raise levels of caffeine, clozapine, olanzapine, and theophylline—so proactive dose/caffeine reductions and monitoring are important during transitions. Pregnancy/breastfeeding: guidance advises behavioral support first; if NRT is used, short-acting forms and daytime patch-only use (remove before bed) can reduce fetal exposure and vivid dreams; overall, NRT is considered far safer than continued smoking, but not risk-free. Timing buccal doses right after breastfeeding can reduce infant exposure. These points guide safer choices for pregnant or lactating people who cannot stop nicotine abruptly. Tobacco smoke (not pure nicotine) contains MAO-inhibiting beta-carbolines that enhance reinforcement; this clarifies that the MAOI warning relates mainly to smoke chemistry, while pharmaceutical MAOIs warrant caution because nicotine is a sympathomimetic. Pharmacokinetics: nicotine’s body half-life is about 2 hours (cotinine ~16–18 h, useful for testing), informing redose spacing and why cravings recur quickly with inhaled use. Practical HR tips embedded above: start low and titrate slowly; avoid stacking different nicotine products simultaneously without a plan; keep liquids locked away from children/pets; wear gloves/eye protection handling high-strength base; remove transdermal patches at night if disturbing dreams; avoid vaping battery misuse/poor-quality cells to reduce explosion/burn risk; and plan caffeine reduction when switching from smoking to nicotine-only delivery.

    ← Back to Nicotine